Time From HIV Infection to Diagnosis in the U.S., 2014–2018


      Understanding the role of sociologic, structural, and biomedical factors that influence the length of time from HIV infection to diagnosis and reducing the time from infection to diagnosis are critical for achieving the goals of the Ending the HIV Epidemic initiative. In a retrospective analysis, the length of time from HIV infection to diagnosis and its association with individual- and facility-level attributes are determined.


      Data reported by December 2019 to the U.S. National HIV Surveillance System for people with HIV diagnosed during 2014–2018 were analyzed during December 2020. A CD4 depletion model was used to estimate the time from HIV infection to diagnosis.


      During 2018, the median time from HIV infection to diagnosis was shorter for those infections diagnosed using the rapid testing algorithm (30.3 months, 95% CI=25.5, 34.5) than those diagnosed using the recommended (41.0 months, 95% CI=39.5, 42.0), traditional (37.0 months, 95% CI=29.5, 43.5), or other (35.5 months, 95% CI=32.5, 38.0) diagnostic testing algorithms. From 2014 to 2018, the time from HIV infection to diagnosis remained stable overall for all testing methods except for the traditional diagnostic testing algorithm. In multivariate analyses, those more likely to have HIV diagnosed closer to the time of infection were younger, were White, had transmission risk factors of injection drug use or heterosexual contact (for female individuals) or male-to-male sexual contact and injection drug use, or had HIV diagnosed at a correctional or screening facility (p<0.01).


      Providing access to expanded testing, including rapid testing in nonclinical settings, is likely to result in a decrease in the length of time a person is unaware of their HIV infection and thus reduce onward transmission of HIV infection.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fauci AS
        • Redfield RR
        • Sigounas G
        • Weahkee MD
        • Giroir BP.
        Ending the HIV Epidemic: a plan for the United States.
        JAMA. 2019; 321: 844-845
      1. What is Ending the HIV Epidemic in the U.S.? Office of Infectious Disease and HIV/AIDS Policy, HHS. Updated June 2, 2021. Accessed June 23, 2021.

        • Dailey AF
        • Hoots BE
        • Hall HI
        • et al.
        Vital signs: human immunodeficiency virus testing and diagnosis delays - United States.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 1300-1306
        • Li Z
        • Purcell DW
        • Sansom SL
        • Hayes D
        • Hall HI.
        Vital signs: HIV transmission along the continuum of care - United States, 2016.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 267-272
        • Hall HI
        • Song R
        • Szwarcwald CL
        • Green T.
        Brief report: time from infection with the human immunodeficiency virus to diagnosis, United States.
        J Acquir Immune Defic Syndr. 2015; 69: 248-251
        • Robertson MM
        • Braunstein SL
        • Hoover DR
        • Li S
        • Nash D.
        Estimates of the time from seroconversion to ART initiation among people newly diagnosed with HIV from 2006 to 2015, New York City.
        Clin Infect Dis. 2020; 71: e308-e315
        • Dangerfield DT
        • Craddock JB
        • Gilreath TD.
        HIV testing and healthcare utilization among U.S. African-American women.
        J Natl Black Nurses Assoc. 2018; 29: 1-8
        • Leblanc NM
        • Flores DD
        • Barroso J.
        Facilitators and barriers to HIV screening: a qualitative meta-synthesis.
        Qual Health Res. 2016; 26: 294-306
        • Delaney KP
        • Hanson DL
        • Masciotra S
        • Ethridge SF
        • Wesolowski L
        • Owen SM.
        Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure.
        Clin Infect Dis. 2017; 64: 53-59
        • Lodi S
        • Phillips A
        • Touloumi G
        • et al.
        Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm3: assessment of need following changes in treatment guidelines.
        Clin Infect Dis. 2011; 53: 817-825
        • Touloumi G
        • Pantazis N
        • Pillay D
        • et al.
        Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.
        Clin Infect Dis. 2013; 56: 888-897
        • Satcher Johnson A
        • Song R
        • Hall HI.
        Estimated HIV incidence, prevalence, and undiagnosed infections in U.S. states and Washington, DC, 2010-2014.
        J Acquir Immune Defic Syndr. 2017; 76: 116-122
        • Szwarcwald CL
        • Ferreira Oda C Júnior
        • Brito AM
        • Luhm KR
        • et al.
        Estimation of HIV incidence in two Brazilian municipalities, 2013.
        Rev Saude Publica. 2016; 50: 55
        • Centers for Disease Control and Prevention
        Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections.
        MMWR Suppl. 1989; 38: 1-7
        • Centers for Disease Control and Prevention
        Laboratory testing for the diagnosis of HIV infection: updated recommendations.
        Centers for Disease Control and Prevention, Atlanta, GA2014 ( Published June 27, 2014. Accessed July 1, 2020)
        • Centers for Disease Control and Prevention
        Implementing HIV testing in nonclinical settings: a guide for HIV testing providers.
        Centers for Disease Control and Prevention, Atlanta, GA2016 ( Published March 2, 2016. Accessed July 1, 2020)
        • Harrison KM
        • Kajese T
        • Hall HI
        • Song R.
        Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach.
        Public Health Rep. 2008; 123: 618-627
        • Kaplan EL
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Cox DR
        • Oakes D.
        Analysis of Survival Data.
        Chapman & Hall/CRC, Boca Raton, FL1984
        • Cox DR.
        Regression models and life-tables.
        J R Stat Soc B (Methodol). 1972; 34: 187-202
      2. HIV testing initiatives: New York knows. NYC Health. Accessed October 30, 2020.

      3. Expanded testing initiative.
        Centers for Disease Control and Prevention, 2020 (Updated May 12, 2020. Accessed June 3, 2021)
        • Branson BM
        • Handsfield HH
        • Lampe MA
        • et al.
        Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.
        MMWR Recomm Rep. 2006; 55 (1-17; quiz CE1-4)
        • Centers for Disease Control and Prevention
        HIV testing trends in the United States; 2000-2011.
        Centers for Disease Control and Prevention, Atlanta, GA2013 ( Published January 2013. Accessed May 4, 2021)
        • Krueger A
        • Van Handel M
        • Dietz PM
        • Williams WO
        • Patel D
        • Johnson AS.
        HIV testing, access to HIV-related services, and late-stage HIV diagnoses across U.S. states, 2013-2016.
        Am J Public Health. 2019; 109: 1589-1595
        • Pharr JR
        • Lough NL
        • Ezeanolue EE.
        Barriers to HIV testing among young men who have sex with men (MSM): experiences from Clark County, Nevada.
        Glob J Health Sci. 2015; 8: 9-17
        • Patel P
        • Bennett B
        • Sullivan T
        • et al.
        Rapid HIV screening: missed opportunities for HIV diagnosis and prevention.
        J Clin Virol. 2012; 54: 42-47
        • Delaney KP
        • Rurangirwa J
        • Facente S
        • et al.
        Using a multitest algorithm to improve the positive predictive value of rapid HIV testing and linkage to HIV care in nonclinical HIV test sites.
        J Acquir Immune Defic Syndr. 2016; 71: 78-86
        • Pitasi MA
        • Delaney KP
        • Brooks JT
        • DiNenno EA
        • Johnson SD
        • Prejean J.
        HIV testing in 50 local jurisdictions accounting for the majority of new HIV diagnoses and seven states with disproportionate occurrence of HIV in rural areas, 2016-2017.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 561-567
        • Maruschak LM
        • Bronson J.
        HIV in prisons, 2015 - statistical tables.
        Bureau of Justice Statistics, Washington, DC2017 ( Published August 2017. Accessed March 3, 2020)
        • Lyss SB
        • Buchacz K
        • McClung RP
        • Asher A
        • Oster AM.
        Responding to outbreaks of human immunodeficiency virus among persons who inject drugs-United states, 2016-2019: perspectives on recent experience and lessons learned.
        J Infect Dis. 2020; 222: S239-S249
        • Cooley LA
        • Wejnert C
        • Spiller MW
        • Broz D
        • Paz-Bailey G
        • NHBS Study Group
        Low HIV testing among persons who inject drugs-National HIV Behavioral Surveillance, 20 U.S. cities, 2012.
        Drug Alcohol Depend. 2016; 165: 270-274
        • Lodi S
        • Phillips A
        • Touloumi G
        • et al.
        CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era.
        AIDS. 2010; 24: 2697-2704
        • Song R
        • Hall HI
        • Green TA
        • Szwarcwald CL
        • Pantazis N.
        Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States.
        J Acquir Immune Defic Syndr. 2017; 74: 3-9
        • Kachur R
        • Hall W
        • Coor A
        • Kinsey J
        • Collins D
        • Strona FV.
        The use of technology for sexually transmitted disease partner services in the United States: a structured review.
        Sex Transm Dis. 2018; 45: 707-712
        • Katz DA
        • Golden MR
        • Hughes JP
        • Farquhar C
        • Stekler JD.
        HIV self-testing increases HIV testing frequency in high-risk men who have sex with men: a randomized controlled trial.
        J Acquir Immune Defic Syndr. 2018; 78: 505-512
        • Sullivan PS
        • Lyons MS
        • Czarnogorski M
        • Branson BM.
        Routine screening for HIV infection in medical care settings: a decade of progress and next opportunities.
        Public Health Rep. 2016; 131: 1-4
        • Walensky RP
        • Reichmann WM
        • Arbelaez C
        • et al.
        Counselor- versus provider-based HIV screening in the emergency department: results from the universal screening for HIV infection in the emergency room (USHER) randomized controlled trial.
        Ann Emerg Med. 2011; 58
        • Weidle PJ
        • Lecher S
        • Botts LW
        • et al.
        HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.
        J Am Pharm Assoc (2003). 2014; 54: 486-492